Vertex Pharmaceuticals VRTX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 344.9%+0.2pp | 344.7%-0.9pp | 344.5%-2.1pp | 344.4%-4.0pp | 344.7%-5.1pp | |
| EBITDA margin | 150.5%+155pp | 106.5%+64.5pp | 70.8%-11.1pp | 33.6%-90.6pp | -4.9%-174pp | |
| Free cash flow margin | 91%+185pp | 29.7%+56.2pp | -24%-58.3pp | -71.1%-174pp | -94%-249pp | |
| Returns | ||||||
| Return on invested capital | 103.9%+112pp | 71.8%+44.5pp | 46.9%-13.0pp | 20%-69.2pp | -8.5%-128pp | |
| Efficiency | ||||||
| Asset turnover | 2×+0.1× | 2×0.0× | 2×0.0× | 2×0.0× | 2×0.0× | |
| Inventory turnover | 4.7×-1.8× | 5.1×-2.0× | 5.5×-2.1× | 6×-2.1× | 6.5×-2.1× | |
| Liquidity | ||||||
| Current ratio | 10.8×+0.5× | 10.4×-0.8× | 10.2×-2.3× | 10.3×-3.8× | 10.3×-5.4× | |
| Quick ratio | 9.2×+0.1× | 8.9×-1.2× | 8.8×-2.7× | 9×-4.2× | 9.1×-5.8× | |
| Cash ratio | 5×-0.1× | 4.9×-1.4× | 4.8×-3.1× | 5×-3.1× | 5.1×-3.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×0.0× | 0.4×+0.1× | 0.4×+0.1× | 0.4×+0.2× | 0.4×+0.2× | |
| Debt-to-assets | 0.3×0.0× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.1× | |
| Net debt / EBITDA | -3×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $281.46+15.2% | $269.49+7.0% | $260.77+2.0% | $253.43-2.2% | $244.33-6.5% | |
| Valuation | ||||||
| Market capitalization | $444.5B-5.3% | $455.56B+0.6% | $444.24B-2.1% | $463.87B+9.5% | $469.26B+19.3% | |
| Enterprise value | $431.37B-5.5% | $442.91B+2.0% | $431.82B+0.7% | $451.09B+13.6% | $456.28B+24.3% | |
| Price / sales | 37.6×-6.1× | 39.5×-3.5× | 39.3×-4.9× | 42×-0.2× | 43.6×+3.6× | |
| Price / book | 24.6×-5.2× | 26.2×-1.8× | 26.4×-1.3× | 28.3×+2.9× | 29.7×+6.7× | |
| EV / EBITDA | 97.1×— | —— | —— | —— | —— | |
| EV / sales | 36.4×-6.0× | 38.4×-2.8× | 38.2×-3.5× | 40.9×+1.3× | 42.4×+5.0× | |
| Free cash flow yield | 9.8%+18.6pp | 3.8%+6.4pp | -1.9%-5.3pp | -6.7%-17.0pp | -8.8%-24.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vertex Pharmaceuticals's profit margins?
- Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.
- Where do Vertex Pharmaceuticals's ratios come from?
- Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
